Australia - English - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - triptorelin embonate, quantity: 5.6 mg (equivalent: triptorelin, qty 3.75 mg) - injection, diluent for - excipient ingredients: water for injections - diphereline is indicated for the treatment of hormone-dependent locally advanced or metastatic prostate cancer.

New Zealand - English - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - atomoxetine hydrochloride 11.43mg equivalent to atomoxetine 10mg - capsule - 10 mg - active: atomoxetine hydrochloride 11.43mg equivalent to atomoxetine 10mg excipient: colloidal silicon dioxide croscarmellose sodium gelatin   magnesium stearate opacode black s-1-277002 starch titanium dioxide   - treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - atomoxetine hydrochloride 114.3mg equivalent to atomoxetine 100mg - capsule - 100 mg - active: atomoxetine hydrochloride 114.3mg equivalent to atomoxetine 100mg excipient: colloidal silicon dioxide croscarmellose sodium gelatin   iron oxide black   iron oxide red   iron oxide yellow   magnesium stearate opacode black s-1-277002 starch titanium dioxide   - treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - atomoxetine hydrochloride 20.574mg equivalent to atomoxetine 18mg - capsule - 18 mg - active: atomoxetine hydrochloride 20.574mg equivalent to atomoxetine 18mg excipient: colloidal silicon dioxide croscarmellose sodium gelatin   iron oxide yellow magnesium stearate opacode black s-1-277002 starch titanium dioxide   - treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - atomoxetine hydrochloride 28.575mg equivalent to atomoxetine 25mg - capsule - 25 mg - active: atomoxetine hydrochloride 28.575mg equivalent to atomoxetine 25mg excipient: colloidal silicon dioxide croscarmellose sodium gelatin   indigo carmine magnesium stearate opacode black s-1-277002 starch titanium dioxide   - treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - atomoxetine hydrochloride 45.72mg equivalent to atomoxetine 40mg - capsule - 40 mg - active: atomoxetine hydrochloride 45.72mg equivalent to atomoxetine 40mg excipient: colloidal silicon dioxide croscarmellose sodium gelatin   indigo carmine   magnesium stearate opacode black s-1-277002 starch titanium dioxide   - treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - atomoxetine hydrochloride 5.715mg equivalent to atomoxetine 5mg - capsule - 5 mg - active: atomoxetine hydrochloride 5.715mg equivalent to atomoxetine 5mg excipient: colloidal silicon dioxide croscarmellose sodium gelatin   iron oxide yellow   magnesium stearate opacode black s-1-277002 starch titanium dioxide   - treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - atomoxetine hydrochloride 68.58mg equivalent to atomoxetine 60mg - capsule - 60 mg - active: atomoxetine hydrochloride 68.58mg equivalent to atomoxetine 60mg excipient: colloidal silicon dioxide croscarmellose sodium gelatin   indigo carmine iron oxide yellow magnesium stearate opacode black s-1-277002 starch titanium dioxide   - treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - atomoxetine hydrochloride 91.44mg equivalent to atomoxetine 80mg - capsule - 80 mg - active: atomoxetine hydrochloride 91.44mg equivalent to atomoxetine 80mg excipient: colloidal silicon dioxide croscarmellose sodium gelatin   iron oxide black iron oxide red iron oxide yellow magnesium stearate opacode black s-1-277002 starch titanium dioxide   - treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - lanreotide acetate, quantity: 149.4 mg (equivalent: lanreotide, qty 125.5 mg) - injection, solution - excipient ingredients: glacial acetic acid; water for injections - somatuline autogel is indicated for: - the treatment of acromegaly when the circulating levels of growth hormone and igf-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory -the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours -the treatment of gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.